Isodiol International Inc.(CSE: ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has initiated the drug approval process through the Brazilian Health Regulatory Agency (ANVISA) for the approval of its pharmaceutical grade cannabidiol (CBD) products for placement in the Special Category List for approved imported CBD products.
As a part of the ANVISA approval process, the Company is also proud to announce physicians are currently prescribing the Isoderm product. “We are extremely excited to have officially entered the South American market for our pharmaceutical grade products,” said Marcos Agramont, Chief Executive Officer of Isodiol Inc.
“We anticipate receiving full approval within the next quarter, which allows us time to develop and implement our commercialization strategy for the Brazilian market. We will continue to develop products and sale channels in North America for our Nutraceutical products however, as the global CBD market evolves, we want to ensure Isodiol is at the forefront of this movement. As leaders in the domestic space, we will ensure Isodiol has a significant presence in the implementation of global standards with health authorities and government officials in turning this CBD movement into a legitimate industry,” said Marcos.
The company has also signed a non-binding letter of intent for an exclusive partnership agreement with an established Brazilian based pharmaceutical importer and distributor, who will provide the following services,

  • Obtain formal ANVISA approval for the products in Brazil,
  • Work exclusively with Isodiol for the importation, promotion, development and sale of products,
  • Sponsor events for physicians, distributors and pharmaceutical companies to spread awareness, educate and promote products.

Additional information will be provided around the financial terms of the partnership agreement in the coming weeks.
About Isodiol International Inc.
Isodiol International, Inc. is the market leader in pharmaceutical grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol’s nutraceutical division is the pioneer of many firsts for Hemp-derived cannabidiol (CBD), including 99% pure crystalline isolate, micro-encapsulation, and nano technology for the highest quality consumable and topical skin care products.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and acquisitions to expand its portfolio of brands and subsidiaries and will aggressively continue International expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
“Marcos Agramont” CEO & Director
COMPANY MEDIA:
Isodiol.com
CBDnaturals.com
Iso-sport.com
CBDskincream.com
Potocoffee.coffee
ir@isodiol.com
Join Us On Face Book: https://www.facebook.com/Isodiol/
Twitter: @isodiol
Forward-Looking Information:
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

Click here to connect with Isodiol International Inc. (CSE: ISOL) to receive an Investor Presentation.


Source: isodiol.com

Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States today announced the appointment of Marcum LLP (“Marcum”) as its independent registered public accounting firm, effective July 5, 2021 . Marcum was appointed following the resignation of MNP LLP (“MNP”) as the Company’s independent registered public accounting firm effective July 5, 2021 .

“We would like to thank MNP for their guidance and expertise over the past two years and we look forward to working with Marcum as the Company’s new independent registered public accounting firm,” stated Chief Financial Officer, Alex D’Amico.

Keep reading... Show less

Cannabis-infused beverages are not a new product concept, but this summer Canadian drink makers hope consumers will discover them for the first time.

Recreational cannabis beverages have beguiled Canadian producers through different avenues, and many continue to make investments. The promise of these drinks lies in the potential of a more welcoming option for new consumers who may be out of their depth with rolled-up dried flower.

Keep reading... Show less

In the news release, BioHarvest Sciences Inc.‘s First Cannabis Cell Reservoir Produces Ongoing Flowering Stage Cannabinoid Cells For 2 Years, issued 07-Jul-2021 by BioHarvest Sciences Inc. over PR Newswire, we are advised by the company that an incorrect version of the release was issued inadvertently. The complete, corrected release follows:

BioHarvest Sciences Inc.‘s First Cannabis Cell Reservoir Produces Ongoing Flowering Stage Cannabinoid Cells For 2 Years

Keep reading... Show less

Trulieve is the first medical cannabis operator to start planting in the state

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today that it commenced operations in West Virginia . The Company has begun cultivation at their 100,000 square foot size facility in Huntington, West Virginia .

Keep reading... Show less

– The Company demonstrates the efficiency and reliability of its BioFarming technology by reducing production cycle time for Cannabis from 14-23 weeks to 3-4 weeks.

– The Company’s BioFarming technology will allow the Company to harvest 13-17 cycles per year versus 2-4 cycles per year for conventional Cannabis agriculture.

Keep reading... Show less